ANGELA ALESI: Open Payments
NPI 1760411318 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,711 in 112 payments from 17 companies in 2025. Trend: 2023 $1,101 · 2024 $1,651 · 2025 $2,711
Food & beverage: $2,711
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $593 |
| Neurocrine BioSciences, Inc. | 9 | $315 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $251 |
| ABBVIE INC. | 8 | $239 |
| Vanda Pharmaceuticals Inc. | 7 | $226 |
| Alkermes, Inc. | 9 | $218 |
| Axsome Therapeutics, Inc. | 5 | $105 |
| Almatica Pharma LLC | 6 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| Teva Pharmaceuticals USA, Inc. | 4 | $97 |
Products named: REXULTI, INGREZZA, CAPLYTA, FANAPT, VRAYLAR, ARISTADA, Auvelity, LOREEV XR.
Industry payments across NV — which companies pay providers there.
